FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213530734> ?p ?o ?g. }

• W3213530734 endingPage "5270" @default.
• W3213530734 startingPage "5270" @default.
• W3213530734 abstract "Patients with bladder cancer have a high risk of venous thrombosis that represents a key challenge for physicians in the decision-making for initiating anticoagulation therapy. Non-muscle-invasive bladder cancer (NMIBC) represents more than 70% of all diagnosed bladder malignancies; therefore, we aimed to evaluate the relationship of the neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and risk of thrombosis by using the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) score as well as the risk of bleeding by using the IMPROVE Bleeding Risk Assessment Score in a study cohort.This was a retrospective observational study involving 130 patients who met the inclusion criteria: age > 18 years, stage pTa-pT1 NMIBC. The exclusion criteria were age < 18 years; stage pT2 or higher; or a presentation of metastasis, inflammatory, liver or autoimmune diseases, or other systemic neoplasms. In order to evaluate the risk of thromboembolic events as well as those of bleeding, the IMPROVE scores were calculated for each patient. Subjects were categorized in a Low IMPROVE group (< 4 points) or a High IMPROVE group. By using uni- and multivariate regression models, we analyzed CBC-derived parameters which could be associated with a higher risk of venous thrombosis in subjects with low or high IMPROVE scores.Patients with IMPROVE score greater than 4 were associated with higher NLR, LMR and lymphocyte values (p < 0.05). In a multivariate regression model, the IMPROVE score was significantly influenced by lymphocyte count (p = 0.007) as well as the NLR value (p < 0.0001).In our study population, subjects with NMIBC with low lymphocytes and NLR > 3 were at a higher risk of developing venous thromboembolic events, reflected by an IMPROVE score of greater than 4. The IMPROVE and IMPROVE Bleeding Risk Assessment Scores are easy to use, and, complemented with the CBC-derived lymphocyte to monocyte ratio as a prothrombotic marker, could aid in the decision of prophylactic anticoagulation therapy during admission." @default.
• W3213530734 created "2021-11-22" @default.
• W3213530734 creator A5007635209 @default.
• W3213530734 creator A5026809809 @default.
• W3213530734 creator A5027708301 @default.
• W3213530734 creator A5032793277 @default.
• W3213530734 creator A5059553692 @default.
• W3213530734 creator A5076476146 @default.
• W3213530734 date "2021-11-12" @default.
• W3213530734 modified "2023-09-26" @default.
• W3213530734 title "Inflammatory Markers and Thromboembolic Risk in Patients with Non-Muscle-Invasive Bladder Cancer" @default.
• W3213530734 cites W1982906652 @default.
• W3213530734 cites W1989925694 @default.
• W3213530734 cites W2019095425 @default.
• W3213530734 cites W2054738316 @default.
• W3213530734 cites W2084672356 @default.
• W3213530734 cites W2117983655 @default.
• W3213530734 cites W2174646679 @default.
• W3213530734 cites W2236848910 @default.
• W3213530734 cites W2306951771 @default.
• W3213530734 cites W2340796010 @default.
• W3213530734 cites W2602722441 @default.
• W3213530734 cites W2612138186 @default.
• W3213530734 cites W2766445207 @default.
• W3213530734 cites W2775018244 @default.
• W3213530734 cites W2790998882 @default.
• W3213530734 cites W2801404059 @default.
• W3213530734 cites W2806012085 @default.
• W3213530734 cites W2888703339 @default.
• W3213530734 cites W2895292626 @default.
• W3213530734 cites W2902174064 @default.
• W3213530734 cites W2902754410 @default.
• W3213530734 cites W2912206780 @default.
• W3213530734 cites W2924354627 @default.
• W3213530734 cites W2926649387 @default.
• W3213530734 cites W2938116464 @default.
• W3213530734 cites W2982756535 @default.
• W3213530734 cites W3006503971 @default.
• W3213530734 cites W3011188024 @default.
• W3213530734 cites W3022217413 @default.
• W3213530734 cites W3182911823 @default.
• W3213530734 cites W3205681684 @default.
• W3213530734 doi "https://doi.org/10.3390/jcm10225270" @default.
• W3213530734 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8617657" @default.
• W3213530734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34830552" @default.
• W3213530734 hasPublicationYear "2021" @default.
• W3213530734 type Work @default.
• W3213530734 sameAs 3213530734 @default.
• W3213530734 citedByCount "2" @default.
• W3213530734 countsByYear W32135307342023 @default.
• W3213530734 crossrefType "journal-article" @default.
• W3213530734 hasAuthorship W3213530734A5007635209 @default.
• W3213530734 hasAuthorship W3213530734A5026809809 @default.
• W3213530734 hasAuthorship W3213530734A5027708301 @default.
• W3213530734 hasAuthorship W3213530734A5032793277 @default.
• W3213530734 hasAuthorship W3213530734A5059553692 @default.
• W3213530734 hasAuthorship W3213530734A5076476146 @default.
• W3213530734 hasBestOaLocation W32135307341 @default.
• W3213530734 hasConcept C11783203 @default.
• W3213530734 hasConcept C121608353 @default.
• W3213530734 hasConcept C126322002 @default.
• W3213530734 hasConcept C143998085 @default.
• W3213530734 hasConcept C167135981 @default.
• W3213530734 hasConcept C2777761686 @default.
• W3213530734 hasConcept C2779134260 @default.
• W3213530734 hasConcept C2780011451 @default.
• W3213530734 hasConcept C2780352672 @default.
• W3213530734 hasConcept C2780868729 @default.
• W3213530734 hasConcept C38180746 @default.
• W3213530734 hasConcept C71924100 @default.
• W3213530734 hasConcept C72563966 @default.
• W3213530734 hasConceptScore W3213530734C11783203 @default.
• W3213530734 hasConceptScore W3213530734C121608353 @default.
• W3213530734 hasConceptScore W3213530734C126322002 @default.
• W3213530734 hasConceptScore W3213530734C143998085 @default.
• W3213530734 hasConceptScore W3213530734C167135981 @default.
• W3213530734 hasConceptScore W3213530734C2777761686 @default.
• W3213530734 hasConceptScore W3213530734C2779134260 @default.
• W3213530734 hasConceptScore W3213530734C2780011451 @default.
• W3213530734 hasConceptScore W3213530734C2780352672 @default.
• W3213530734 hasConceptScore W3213530734C2780868729 @default.
• W3213530734 hasConceptScore W3213530734C38180746 @default.
• W3213530734 hasConceptScore W3213530734C71924100 @default.
• W3213530734 hasConceptScore W3213530734C72563966 @default.
• W3213530734 hasIssue "22" @default.
• W3213530734 hasLocation W32135307341 @default.
• W3213530734 hasLocation W32135307342 @default.
• W3213530734 hasLocation W32135307343 @default.
• W3213530734 hasLocation W32135307344 @default.
• W3213530734 hasOpenAccess W3213530734 @default.
• W3213530734 hasPrimaryLocation W32135307341 @default.
• W3213530734 hasRelatedWork W1979321249 @default.
• W3213530734 hasRelatedWork W2154967465 @default.
• W3213530734 hasRelatedWork W2466616124 @default.
• W3213530734 hasRelatedWork W2603773853 @default.
• W3213530734 hasRelatedWork W2728821615 @default.
• W3213530734 hasRelatedWork W2746714976 @default.
• W3213530734 hasRelatedWork W3195454649 @default.

• next